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ABSTRACT 
BACKGROUND: P-glycoprotein (P-gp), an ABC transport protein 
contributes to the interpatient pharmacokinetic and 
pharmacodynamic variability of calcineurin inhibitors(CNI), 
tacrolimus(TAC) and cyclosporine (CYA). ABCB1 encodes P-gp and the 
single nucleotide polymorphisms (SNP) 1236C>T, 2677G>T/A, 
3435C>T may alter protein expression or function. Our objective was 
to examine the association of ABCB1 haplotypes, sex and race with 
chronic CNI adverse effects (AE) in renal transplant recipients (RTR).  
METHODS: A meta-analysis of 3 prospective observational studies 
was completed in 149 stable RTR [GFR= 51 ±17 ml/min/1.73m2 ] 
using identical inclusion and exclusion criteria in 62 African 
Americans (AA) and 81 Caucasians (C) treated with CYA (troughs: 50-
150 ng/ml) and mycophenolate mofetil or TAC (troughs: 5-10 ng/ml) 
and mycophenolate sodium. Each RTR had AE assessed using 
standardized objective scales by study physicians. A Cumulative AE 
ratio was determined using 14 AE. Separate gastrointestinal (GI), 
central nervous system (CNS), and aesthetic AE ratios were also 
assessed. DNA from peripheral blood mononuclear cells was collected 
to characterize ABCB1 SNPs completed on 11/15/12. Haplotype 
computation and association with AE was completed by THESIAS 
program on 12/3/12.  
RESULTS: All genotypes were in Hardy-Weinberg equilibria. AA had a 
greater frequency of the C-G-C haplotype (SNPs: 1236-2677-3435) 
compared to C (71.6% vs. 44.2%; p<0.001). A gender difference was 
noted for Cumulative (p<0.001); GI (p=0.046); aesthetic (p=0.0002) 
and CNS (p=0.051) AE ratios with greater AE ratios in females. The 
Aesthetic AE ratio was associated with haplotype T-T-C (p=0.008). 
Haplotype C-T-T was associated with increased GI AE ratio (p=0.02) 
though the effect was not significant when sex was included as a 
covariate (p=0.13). Race had no associations with AE.  
CONCLUSION: RTR receiving CNI based immunosuppression within 
the therapeutic range exhibited interpatient variability in AE with 
associations to sex and ABCB1 haplotypes. 
  
INTRODUCTION 
CONCLUSIONS 
• Female sex significantly increases the 
cumulative incidence of adverse effects 
associated with calcineurin inhibitor based 
immunosuppression 
• A racial difference in ABCB1 haplotype 
distribution exists 
• The common ABCB1 haplotype TTT, often 
identified as having decreased P-gp function, is 
not significantly associated with increased 
adverse effects 
• CTT and TTC haplotypes are associated with 
increased GI and Aesthetic AEs, respectively 
o This association is largely driven by sex as a 
covariate 
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METHODS 
Study Design 
• Meta-analysis of three observational pharmacokinetic-pharmacodynamic studies 
Objectives 
• Determine influence of sex and ABCB1 haplotypes on cumulative incidence of adverse effects (AEs) associated 
with calcineurin inhibitor based maintenance immunosuppression  
post-renal transplant 
Adverse Effects 
• Quantitated using objective, standardized, nephrologist administered  
assessment tool 
Genomics 
• Genomic DNA isolated from 600mcl of peripheral blood mononuclear  
cells (Wizard® Genomic DNA Purification) 
• 10ng of genomic DNA used to characterize SNPs in  ABCB1   
(1236, 2677, 3435) 
• Taqman™ allelic discrimination assay 
• CFX96 Real-Time PCR detection system 
• Genotype results for 141 patients utilized for haplotype analysis 
• Haplotype frequencies computed by THESIAS®  
Statistics 
• General linear modeling employed for Cumulative, GI, and Aesthetic  
AE Ratios 
• Logistic regression model employed for individual AEs and CNS AE Ratio 
• Type of CNI, sex, race, and race X sex interaction as base model grouping variables 
• Association of haplotypes with AEs using maximum likelihood estimates with 95% confidence intervals and Chi-
Square test for comparison 
• Statistical analysis performed with SAS® version 9.3 and THESIAS® version 3.1 
RESULTS 
FUTURE DIRECTIONS 
Table 1. Adverse Effect Grouping 
AE Group AEs Included 
Cumulative Acne, tremor, myopathy, 
hirsutism, skin changes, 
insomnia, headache, 
vomiting, diarrhea, 
dyspepsia, PPI, H2RA, 
gingival hyperplasia, post-
transplant diabetes 
Gastrointestinal 
(GI) 
Vomiting, diarrhea, 
dyspepsia, PPI, H2RA 
Central Nervous 
System (CNS) 
Headache, tremor, insomnia 
Aesthetic Acne, gingival hyperplasia, 
skin changes, hirsutism 
Table 2.  Demographic, Laboratory, and Clinical Parameters 
Males (n=106) Females (n=43) P value 
CYA+ MMF 68 (64.2%) 14 (32.6%) 0.0004 
TAC+EC-MPS 38 (35.8%) 29 (67.4%) 0.0004 
Age (years) 50.9 (10.5) 51.0 (12.1) 0.937 
Time post-transplant (years) 4.28 (3.45) 3.23 (2.63) 0.089 
Total weight (kg) 94.1 (19.1) 76.2 (20.0) <0.0001 
BMI (kg/m2) 30.5 (5.79) 28.8 (6.80) 0.063 
Systolic BP (mmHg) 139 (22) 139 (24) 0.901 
Diastolic BP (mmHg) 80 (12) 81 (9) 0.550 
Glucose (mg/dl) 115 (63) 109 (62) 0.037 
Total cholesterol (mg/dl) 171 (50) 182 (48) 0.220 
Total WBC (cells/mm3) 5.8 (2.0) 5.6 (1.9) 0.486 
Hemoglobin (g/dl) 12.9 (1.4) 11.9 (1.2) <0.0001 
Albumin (g/dl) 4.1 (0.4) 3.9 (0.4) 0.010 
Serum creatinine (mg/dl) 1.68 (0.54) 1.40 (0.45) 0.0008 
Adjusted eGFR (ml/min/1.73m2) 49.0 (16.8) 49.1 (17.3) 0.987 
MPA 12hr conc. (mg/l) 2.71 (1.96) 3.64 (2.20) 0.008 
MPAG 12 hr con. (mg/l) 84.8 (52.6) 91.8 (56.8) 0.546 
Adjusted MPA Dose (mg) 701 (212) 607 (180) 0.011 
TAC trough (ng/ml) 7.3 (2.0) 7.1 (1.8) 0.604 
CYA trough (ng/ml) 131 (47) 127 (46) 0.675 
Prednisone use 40 (37.7%) 14 (32.6%) 0.551 
Statin use 46 (43.4%) 18 (41.9%) 0.864 
CYA=Cyclosporine; MMF=Mycophenolate mofetil; TAC=tacrolimus; EC-MPS=Enteric coated 
mycophenolate sodium; BMI=Body mass index; BP=Blood pressure; eGFR=estimated glomerular 
filtration rate (using 4 factor MDRD equation); MPA=Mycophenolic acid; MPAG=Mycophenolic acid 
glucuronide 
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Main effects p value with sex as covariate: 
• TTC haplotype: p=0.30 for Cumulative; p=0.02 for 
Aesthetic 
• CTT haplotype: p=0.13 for GI 
• Validation of AE assessment tool 
• Additional genotyping 
• ABCC2, CYP3A4, CYP3A5, OATP1, UGTs 
• Pharmacokinetic analysis  
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